In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

Stopped early · Phase 1/Phase 2

Conditions studied: Graft Versus Host Disease

In brief

In this study the investigators are proposing to treat patients with steroid-refractory Graft-versus-host Disease (GVHD) stabilization using IL-2 and azacitidine

Key facts

Study ID
NCT01453140
Run by
Hackensack Meridian Health
People needed
3
Starts
2011-08-01
Expected to finish
2012-07-01
Last updated by the study team
2026-04-08

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.